JP2024001073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024001073A5 JP2024001073A5 JP2023165289A JP2023165289A JP2024001073A5 JP 2024001073 A5 JP2024001073 A5 JP 2024001073A5 JP 2023165289 A JP2023165289 A JP 2023165289A JP 2023165289 A JP2023165289 A JP 2023165289A JP 2024001073 A5 JP2024001073 A5 JP 2024001073A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000012634 fragment Substances 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 12
- 102100034256 Mucin-1 Human genes 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000000611 antibody drug conjugate Substances 0.000 claims 3
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023165289A JP2024001073A (ja) | 2017-10-24 | 2023-09-27 | 抗グリコｍｕｃ１抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020543460A JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
| PCT/US2017/058036 WO2019083506A1 (en) | 2017-10-24 | 2017-10-24 | ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF |
| JP2023165289A JP2024001073A (ja) | 2017-10-24 | 2023-09-27 | 抗グリコｍｕｃ１抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543460A Division JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024001073A JP2024001073A (ja) | 2024-01-09 |
| JP2024001073A5 true JP2024001073A5 (enExample) | 2024-04-24 |
Family
ID=66247577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543460A Active JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
| JP2023165289A Pending JP2024001073A (ja) | 2017-10-24 | 2023-09-27 | 抗グリコｍｕｃ１抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543460A Active JP7358367B2 (ja) | 2017-10-24 | 2017-10-24 | 抗グリコｍｕｃ１抗体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3700936A4 (enExample) |
| JP (2) | JP7358367B2 (enExample) |
| KR (2) | KR102832078B1 (enExample) |
| CN (1) | CN111479828B (enExample) |
| AU (1) | AU2017436815B2 (enExample) |
| BR (1) | BR112020008001A2 (enExample) |
| CA (1) | CA3078812A1 (enExample) |
| IL (1) | IL274202A (enExample) |
| MX (1) | MX2020004220A (enExample) |
| WO (1) | WO2019083506A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017436815B2 (en) * | 2017-10-24 | 2025-05-29 | Go Therapeutics, Inc. | Anti-glyco-muc1 antibodies and their uses |
| US11970546B2 (en) * | 2020-07-31 | 2024-04-30 | R.P. Scherer Technologies, Llc | Antibody specific for Mucin-1 and methods of use thereof |
| AU2022333837A1 (en) * | 2021-08-27 | 2024-03-14 | Peptron, Inc. | Novel anti-muc1 antibody and use thereof |
| US20230250190A1 (en) * | 2021-12-21 | 2023-08-10 | Merus N.V. | Binding domains against cancer-associated muc1 |
| CN114796498A (zh) * | 2022-01-27 | 2022-07-29 | 中国农业大学 | 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用 |
| WO2024213106A1 (zh) * | 2023-04-13 | 2024-10-17 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和muc1的抗原结合分子、其药物偶联物及其医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4976001A (en) * | 2000-03-30 | 2001-10-15 | Dyax Corp | Mucin-1 specific binding members and methods of use thereof |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| JP2010505775A (ja) * | 2006-10-04 | 2010-02-25 | クーベンハヴンス・ユニヴェルシテット | Ｍｕｃ１に対する癌特異的な免疫反応の産生及び癌特異的ｍｕｃ１抗体 |
| EP2014302A1 (en) * | 2007-07-12 | 2009-01-14 | Institut Curie | An antibody specific for the Tn antigen for the treatment of cancer |
| CA2707689A1 (en) * | 2007-12-05 | 2009-06-11 | Kyowa Hakko Kirin Co., Ltd. | Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| CN102264765B (zh) * | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
| EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| US20170145108A1 (en) * | 2014-02-05 | 2017-05-25 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| AU2015254257B2 (en) * | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
| AU2017436815B2 (en) * | 2017-10-24 | 2025-05-29 | Go Therapeutics, Inc. | Anti-glyco-muc1 antibodies and their uses |
-
2017
- 2017-10-24 AU AU2017436815A patent/AU2017436815B2/en active Active
- 2017-10-24 BR BR112020008001-2A patent/BR112020008001A2/pt unknown
- 2017-10-24 EP EP17929557.1A patent/EP3700936A4/en active Pending
- 2017-10-24 JP JP2020543460A patent/JP7358367B2/ja active Active
- 2017-10-24 KR KR1020237040745A patent/KR102832078B1/ko active Active
- 2017-10-24 CA CA3078812A patent/CA3078812A1/en active Pending
- 2017-10-24 KR KR1020207014390A patent/KR102608763B1/ko active Active
- 2017-10-24 WO PCT/US2017/058036 patent/WO2019083506A1/en not_active Ceased
- 2017-10-24 MX MX2020004220A patent/MX2020004220A/es unknown
- 2017-10-24 CN CN201780097773.8A patent/CN111479828B/zh active Active
-
2020
- 2020-04-23 IL IL274202A patent/IL274202A/en unknown
-
2023
- 2023-09-27 JP JP2023165289A patent/JP2024001073A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024001073A5 (enExample) | ||
| EP4039707A1 (en) | Cd3-targeting antibody, bispecific antibody and use thereof | |
| EP3353213B1 (en) | Anti-mesothelin antibody and composition comprising the same | |
| JP2019116474A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| AU2020352382A1 (en) | Anti-human claudin 18.2 antibody and application thereof | |
| JP2021503455A5 (enExample) | ||
| AU2018218753A1 (en) | Anti-GPRC5D antibody and molecule containing same | |
| JP2013502913A5 (enExample) | ||
| KR20220111308A (ko) | 인간화 cldn18.2 항체 | |
| AU2017379382A1 (en) | Anti-CD3 Antibody and Molecules Comprising the Antibody | |
| EP4155320A1 (en) | Anti-b7h4 antibody, and bispecific antibody and use thereof | |
| CN115052895A (zh) | 抗SIRPα抗体及其用途 | |
| TW202241944A (zh) | 新穎的抗ｇｒｅｍｌｉｎ１抗體 | |
| JP2020522488A5 (enExample) | ||
| CN106243223B (zh) | 抗人pdl1抗体及其用途 | |
| JPWO2020114480A5 (enExample) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| CN114829405A (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 | |
| JPWO2019185040A5 (enExample) | ||
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use | |
| JPWO2022104236A5 (enExample) | ||
| JP7641292B2 (ja) | 抗ｃｄ１９抗体、その使用方法及び製造方法 |